NO163814B - Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-substituerte 4-hydroksymetyl-pyrrolidinon-derivater. - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-substituerte 4-hydroksymetyl-pyrrolidinon-derivater. Download PDFInfo
- Publication number
- NO163814B NO163814B NO843004A NO843004A NO163814B NO 163814 B NO163814 B NO 163814B NO 843004 A NO843004 A NO 843004A NO 843004 A NO843004 A NO 843004A NO 163814 B NO163814 B NO 163814B
- Authority
- NO
- Norway
- Prior art keywords
- hydroxymethyl
- pyrrolidin
- general formula
- substituted
- carbon atoms
- Prior art date
Links
- -1 1-SUBSTITUTED 4-HYDROXYMETHYL-PYRROLIDINON Chemical class 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 4
- 239000000460 chlorine Substances 0.000 claims abstract description 4
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
- 239000011737 fluorine Substances 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- YBBZCXJUQRZHDD-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)CC(CO)C1 YBBZCXJUQRZHDD-UHFFFAOYSA-N 0.000 claims description 2
- KJNWTBGLUKBKME-UHFFFAOYSA-N 1-benzyl-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound O=C1CC(CO)CN1CC1=CC=CC=C1 KJNWTBGLUKBKME-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 4
- GSKFDYBBQXNJJV-UHFFFAOYSA-N 4-(hydroxymethyl)-1-[(4-methoxyphenyl)methyl]pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)CC(CO)C1 GSKFDYBBQXNJJV-UHFFFAOYSA-N 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 abstract description 3
- 230000001777 nootropic effect Effects 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 4
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000004040 pyrrolidinones Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KTOFYLXSANIPND-UHFFFAOYSA-N 4-(hydroxymethyl)pyrrolidin-2-one Chemical class OCC1CNC(=O)C1 KTOFYLXSANIPND-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- VCVHCJHNQOLOGK-UHFFFAOYSA-N ethyl 1-[(3,4-dimethoxyphenyl)methyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OCC)CN1CC1=CC=C(OC)C(OC)=C1 VCVHCJHNQOLOGK-UHFFFAOYSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- FVMMQEKVNTYZJP-UHFFFAOYSA-N 1-[(4-chloro-2-methylphenyl)methyl]-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound CC1=CC(Cl)=CC=C1CN1C(=O)CC(CO)C1 FVMMQEKVNTYZJP-UHFFFAOYSA-N 0.000 description 1
- JBXKWPWEZMUSBG-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound O=C1CC(CO)CN1CC1=CC=C(F)C=C1 JBXKWPWEZMUSBG-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- PKPSLTUBHOIVDF-UHFFFAOYSA-N 4-(hydroxymethyl)-1-[(4-hydroxyphenyl)methyl]pyrrolidin-2-one Chemical compound O=C1CC(CO)CN1CC1=CC=C(O)C=C1 PKPSLTUBHOIVDF-UHFFFAOYSA-N 0.000 description 1
- GRZUUSOQYZMQLB-UHFFFAOYSA-N 4-(hydroxymethyl)-1-[1-(4-methoxyphenyl)ethyl]pyrrolidin-2-one Chemical compound C1=CC(OC)=CC=C1C(C)N1C(=O)CC(CO)C1 GRZUUSOQYZMQLB-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010001596 Alcohol induced persisting dementia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- ZWWQRMFIZFPUAA-UHFFFAOYSA-N dimethyl 2-methylidenebutanedioate Chemical compound COC(=O)CC(=C)C(=O)OC ZWWQRMFIZFPUAA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ATQNUIAAJGJKPE-UHFFFAOYSA-N ethyl 1-[(4-fluorophenyl)methyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OCC)CN1CC1=CC=C(F)C=C1 ATQNUIAAJGJKPE-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Catalysts (AREA)
Description
Denne oppfinnelse angår en analogifremgangsmåte for
fremstilling av nye, i 1-stilling substituerte 4-hydroksymetyl-pyrrolidinon-derivater som kan anvendes i farmasøytiske preparater. Videre beskrives nye syrer og estere som anvendes som mellomprodukter. De nye forbindelser fremstilt ifølge oppfinnelsen har ved dyreforsøk vist seg å være virksomme til å forbedre eller oppheve tilstander med begrenset cerebral ytelsesevne.
Som strukturelt lignende oppbyggede nootropika er 1-karba-moylmetyl-pyrrolidin-2-on (Pirazetam), 1-(p-metoksybenzoyl)-pyrrolidin-2-on (Anirazetam) og l-karbamoylmetyl-4-hydroksy-pyr-rolidin-2-on (Oxirazetam) beskrevet i litteraturen, se B.J.R.
Nicolaus, Drug Development Res. 2, 464 (1982), P.L. Paytasch, J.Amer.Chem. Soc. 72, 1415 (1950).
Overraskende er det nå funnet at en forholdsvis liten for-
andring i molekylet fører til en ganske vesentlig forbedring av virkningen av de kjente nootropika.
Foreliggende oppfinnelse angår en fremgangsmåte for frem-
stilling av nye, i 1-stilling substituerte 4-hydroksymetyl-pyrrolidinon-derivater med den generelle formel
hvor
R^ betyr hydrogen eller en alkylrest med 1, 2, 3 eller 4 karbon-
atomer, og
R2 betyr en eventuelt med alkyl med 1-2 karbonatomer, alkoksy
med 1-2 karbonatomer, fluor, klor, brom, trifluormetyl, ni-
tro, benzyloksy eller hydroksy mono-, di- eller tri-substitu-
ert fenylrest eller en pyridylrest.
Særlig skal fremheves slike forbindelser med den generelle
formel I som bærer en usubstituert eller en med metoksy mono-,
di- eller tri-substituert fenylring.
De nye forbindelser har et asymmetrisentrum og foreligger
således som racemater. Disse racemater kan på vanlig måte, f.eks.
ved forestring med optisk aktive syrer, overføres til de tilsva-
rende optisk aktive estere som deretter kan forsepes til de op-tiske aktive former av sluttproduktene.
Som mellomprodukter ved deres fremstilling anvendes nye syrer og estere med den generelle formel
hvor
betyr hydrogen eller en alkylrest med 1, 2, 3 eller 4 karbonatomer ,
R2 betyr en med alkyl med 1-2 karbonatomer, alkoksy med 1-2
karbonatomer, fluor, klor, brom, trifluormetyl, nitro, benzyloksy eller hydroksy mono-, di- eller tri-substituert fenylrest eller en pyridylrest, og
R betyr en av restene -COOH og -COO-lavere-alkyl.
De nye forbindelser med den generelle formel I fremstilles ifølge oppfinnelsen ved at en pyrrolidinon-4-karboksylsyreester med den generelle formel
hvor
R^ og R2 har den ovenfor angitte betydning, reduseres selektivt med et komplekst alkali-borhydrid.
Den selektive reduksjon foretas med komplekse alkali-bor-hydrider under opprettholdelse av amidfunksjonen i ringen. Som oppløsningsmidler for reduksjonen kan anvendes lavere alkoholer såsom metanol eller butanol, eventuelt under vanntilsetning. Reaksjonstemperaturen ligger mellom -5°C og alkoholens kokepunkt.
For fremstilling av en forbindelse med den generelle formel I hvor R2 betyr en hydroksysubstituert fenylrest og R^ har den ovenfor angitte betydning, hydrogeneres katalytisk en forbindelse med den generelle formel I hvor R2 betyr en tilsvarende benzyloksysubstituert fenylrest.
Hydrogeneringen foretas hensiktsmessig i nærvær av et or-ganisk oppløsningsmiddel, f.eks. metanol, og en hydrogenerings-katalysator, f.eks. Pd/C.
De som mellomprodukter anvendte syrer og estere med den generelle formel II kan fremstilles av ekvimolare mengder av itakonsyre og de tilsvarende aminer med eventuelt påfølgende forestring i henhold til det følgende skjema:
R-j = lavere alkyl
I mange tilfeller er det dessuten mulig å gå ut fra en ita-konsyreester med den generelle formel
og omsette denne direkte med det ønskede amin til esteren II.
Cykloaddisjonen til pyrrolidinon-karboksylsyren kan skje i kokende vann eller uten oppløsningsmiddel, hensiktsmessig i en inertgassatmosfære, f.eks. N2 ved temperaturer på 100 - 150°C.
Med den ovenfor beskrevne fremgangsmåte kan f.eks. de føl-gende sluttprodukter fremstilles: l-benzyl-4-hydroksymetyl-pyrrolidin-2-on
1-(2-metoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(3-metoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(4-metoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(3,4-dimetoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(3,4,5-trimetoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(4-metylbenzyl)-4-hydroksymetyl-pyrrolidin-2-on
1-(4-klorbenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(2-klorbenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(4-fluorbenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(3-trifluormetylbenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(3-hydroksy-4-metoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(3-metoksy-4-hydroksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(2-metyl-4-klorbenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(a-metylbenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-(a-metyl-4-metoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on 1-pyridyl-(2)-metyl-4-hydroksymetyl-pyrrolidin-2-on 1-pyridyl-(3)-metyl-4-hydroksymetyl-pyrrolidin-2-on 1-pyridyl-(4)-metyl-4-hydroksymetyl-pyrrolidin-2-on 1-(4-hydroksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on.
De nye pyrrolidinon-derivater er ved dyreforsøk undersøkt med hensyn til sin virkning til å oppheve eller redusere tilstander med begrenset cerebral ytelsesevne.
Forbindelsene viser ved orienterende forlikelighetsundersø-kelser på mus i doseringer opptil 2 g/kg (en gang oral administrering) ingen akutt toksisitet (14 dager etter observasjon)•
De viser dyreeksperimentelt utmerkede virkninger på spontane kognitive ytelser, såsom eksperimentelt begrensede lære- og hu-kommelsesforløp. Ved forsøk med innskrenkning av korttidshukom-melsen resp. hindring av overgangen av innhold av korttidshukom-melsen til langtidshukommelsen ved administrering av en muscarin-kolinerg antagonist (Skopolamin 0,6 mg/kg i.p.; se også Psycho-pharmacology 78, 104 - 111 (1982)), er forbindelsene i stand til å motvirke denne farmakologisk fremkalte, cerebrale svikt eller å oppheve den.
Læreevnen hos rotter ved en aktiv unngåelsesdressur (J. pharamcol. Methods, 8, 255 - 263 (1983) forbedres likeledes, slik som deres spontane tilpasning eller utforskende oriente-ringsaktivitet i en ny omgivelse.
De nye pyrrolidinon-derivater ble sammenlignet med hensyn til sin virkning med andre typer pyrrolidinon-derivater, som i tilknytning til cerebral svikt resp. hjerneorganisk psykodrom, posttraumatisk og alkoholisk hjerneskade osv., allerede anvendes i humanmedisinen som legemiddel (Pirazetam) resp. for tiden un-dersøkes klinisk (Anriazetam).
De nye forbindelser er med hensyn til den oppnådde ytelsesforbedring ved dyreforsøk klart overlegne i forhold til de nevnte forbindelser.
De nye forbindelser kan anvendes alene eller i kombinasjon med andre virkestoffer fremstilt ifølge oppfinnelsen, eventuelt også i kombinasjon med andre farmakologisk aktive virkestoffer, f.eks. andre cerebroaktivatorer. Egnede anvendelsesformer er f.eks. tabletter, kapsler, stikkpiller, oppløsninger, safter, emulsjoner eller dispergerbare pulvere. Passende tabletter kan f.eks. oppnås ved å blande virkestoffet eller virkestoffene med kjente hjelpestoffer, f.eks. inerte fortynningsmidler såsom kal-siumkarbonat, kalsiumfosfat eller melkesukker, sprengmidler såsom maisstivelse eller alginsyre, bindemidler såsom stivelse eller gelatin, smøremidler såsom magnesiumstearat eller talk, og/ eller midler for å oppnå en depotvirkning, såsom karboksypoly-metylen, karboksymetylcellulose, celluloseacetatftalat eller polyvinylacetat. Tablettene kan også bestå av flere skikt.
Tilsvarende kan drageer fremstilles ved at kjerner fremstilt analogt med tablettene overtrekkes med midler som er vanlige i drageeovertrekk, f.eks. kollidon eller skjellakk, gummi arabicum, talk, titandioksyd eller sukker. For å oppnå en depotvirkning eller for å unngå uforlikeligheter kan kjernen også bestå av flere skikt. Likeledes kan også drageeovertrekket bestå av flere skikt for å oppnå en depotvirkning, idet de ovenfor for
tablettene nevnte hjelpestoffer kan anvendes.
Safter av de nye virkestoffer eller virkestoffkombinasjoner kan dessuten inneholde et søtningsmiddel såsom sakkarin, cyklamat, glycerol eller sukker, samt et smaksforbedrende middel, f.eks. aromastoffer såsom vanilin eller appelsinekstrakt. De kan dessuten inneholde suspenderingshjelpestoffer eller fortyk-ningsmidler såsom natriumkarboksymetylcellulose, fuktemidler såsom kondensasjonsprodukter av fettalkoholer med etylenoksyd, eller beskyttelsesstoffer såsom p-hydroksybenzoater.
Injeksjonsoppløsninger fremstilles på vanlig måte, f.eks. under tilsetning av konserveringsmidler såsom p-hydroksybenzoater, eller stabilisatorer såsom alkalisalter av etylendiamintet-raeddiksyre, og fylles i injeksjonsflasker eller ampuller.
Kapsler inneholdende ett eller flere virkestoffer eller virkestoffkombinasjoner kan f.eks. fremstilles ved at virkestoffene blandes med inerte bæremidler såsom melkesukker eller sor-bitol og innkapsles i gelatinkapsler.
Egnede stikkpiller kan f.eks. fremstilles ved blanding med passende bæremidler såsom nøytrale fettyper eller polyetylengly-kol eller derivater derav.
De følgende eksempler skal tjene til å illustrere oppfinnelsen ytterligere.
EKSEMPEL 1
1- (3,4-dimetoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on
8,0 g 1- (3,4-dimetoksybenzyl)-4-etoksykarbonylpyrrolidin-2- on oppløses i 100 ml metanol. Under mekanisk omrøring tilsetter man dråpevis i 20 minutter ved 0 - 10°C en oppløsning av 2,8 g natriumborhydrid i 30 ml vann og omrører i ytterligere 5 timer ved 0 - 10°C. Deretter dekomponeres overskudd av borhydrid forsiktig ved tilsetning av iseddik til en pH på 5 og til gassutviklingen opphører, og metanolen avdestilleres i vakuum. Man tilsetter noe vann og opptar reaksjonsproduktet i metylenklorid. Metylenkloridfasen vaskes deretter, tørkes og inndampes. Residuet kromatograferer man over silikagel (eluering med metylenklorid/metanol 98 : 2). Fra eluatet får man endelig 4,8 g = 62% av det teoretiske av tittelforbindelsen med et smeltepunkt 78 - 79°C.
Utgangsesteren ble oppnådd som følger:
a) 6,0 g (46 mMol) itakonsyre og 7,7 g.(46 mMol) 3,4-dimetok-sybenzylamin oppvarmes til 130°C under en nitrogenatmosfære
i 2 timer. Etter avkjøling til ca. 100°C setter man under mekanisk omrøring 70 ml 10% natronlut til den seigtflytende reaksjonsblanding og avkjøler deretter til romtemperatur. For å fjerne uoppløselige bestanddeler utrister man natri-umsaltoppløsningen med 50 - 100 ml etylacetat og surgjør den vandige fase med fortynnet saltsyre. Den utfelte olje opptas i metylenklorid, og metylenkloridfasen tørkes og inndampes. Residuet krystalliserer ved etertilsetning. Man får 8,7 g, 68% 1-(3,4-dimetoksybenzyl)-4-karboksy-pyrroli-
o
din-2-on med sm.p. 176 - 178 C.
b) 8,6 g (30 mMol) av syren oppløses i 120 ml absolutt etanol, og oppløsningen kokes i 2 timer under tilbakeløpskjøling mens man stadig fører inn tørr HCl-gass. Deretter avdestilleres overskudd av alkohol i vakuum, og residuet bringes til pH 8 med 30% sodaoppløsning under avkjøling. Etter utristing med metylenklorid, vasking, tørking og avdampning av oppløsningsmiddelet får man ca. 10 g 1-(3,4-dimetoksybenzyl)-4-etoksykarbonyl-pyrrolidin-2-on som en gul olje, som kan omsettes videre i rå tilstand.
Den ifølge b) oppnådde ester kan også fremstilles ved den følgende fremgangsmåte: 10 g (0,064 Mol) itakonsyredimetylester og 7,7 g (0,064 Mol) a-fenyletylamin omrøres i 2 timer ved 120 - 130°C under ni-trogen atmosfære . Reaksjonsproduktet destilleres deretter frak-sjonert ved 150 - 155°C og 0,1 Torr. Man får 9,5 g = 61% av det teoretiske av en lys olje som anvendes uforandret til selektiv reduksjon.
EKSEMPEL 2
1-(p-fluorbenzyl)-4-hydroksymetyl-pyrrolidin-2-on
4,0 g (16 Mol) 1-(p-fluorbenzyl)-4-etoksykarbonyl-pyrroli-din-2-on oppløses i 60 ml tertiær butanol og tilsettes 1,5 g natriumborhydrid. Man bringer blandingen til tilbakeløpstempe-ratur og tilsetter deretter 12 ml tørr metanol litt etter litt i 1 time.
Etter ytterligere 1 time inndampes reaksjonsblandingen i vakuum. Residuet fortynner man med vann, utrister tittelforbindelsen med metylenklorid og opparbeider som beskrevet under eksempel 1. Utbyttet av ren tittelforbindelse utgjør 2,5 g med smeltepunkt 121 - 122°C, dvs. 72% av det teoretiske, basert på råesteren.
Esteren ble fremstilt som følger:
7 g (54 mMol) itakonsyre og 6,8 g (54 mMol) 4-fluor-benzyl-amin kokes sammen med 50 ml vann i 3 timer under tilbakeløpskjø-ling. Deretter gjør man reaksjonsblandingen tydelig alkalisk med 10% natronlut, utrister de vannuoppløselige bestanddeler med etylacetat og surgjør den vandige fase med HC1. Den videre opp-arbeidelse skjer analogt med eksempel 1. Man får lysebrune krys-taller av den tilsvarende karboksylsyre med smeltepunkt 152 - 153°C, som forestres som beskrevet i eksempel 1.
Ved den ovenfor beskrevne fremgangsmåte ble de i den føl-gende tabell angitte sluttprodukter oppnådd via de likeledes angitte karboksylsyrer:
Claims (5)
1. Analogifremgangsmåte for fremstilling av terapeutisk aktive, i 1-stilling substituerte 4-hydroksymetyl-pyrrolidinon-
derivater med den generelle formel
hvor betyr hydrogen eller en alkylrest med 1, 2, 3 eller 4 karbon
atomer, og
R2 betyr en eventuelt med alkyl med 1-2 karbonatomer, alkoksy
med 1-2 karbonatomer, fluor, klor, brom, trifluormetyl,
nitro, benzyloksy eller hydroksy mono-, di- eller tri-substi
tuert fenylrest eller en pyridylrest,
karakterisert ved at a) en pyrrolidinon-4-karboksylsyreester med den generelle
formel
hvor R^ og R2 har den ovenfor angitte betydning, og R^ betyr en lavere alkylgruppe, reduseres selektivt med et komplekst
alkali-borhydrid, eller b) for fremstilling av en forbindelse med den generelle
formel I hvor R2 betyr en hydroksysubstituert fenylrest og R^ har den ovenfor angitte betydning, hydrogeneres katalytisk en forbindelse med den generelle formel I hvor R2 betyr en tilsvarende benzyloksy-substituert fenylrest.
2. Fremgangsmåte ifølge krav 1 for fremstilling av en forbindelse med formel I hvor betyr hydrogen eller en alkylrest•med 1, 2, 3 eller 4 karbonatomer, og R2 betyr en eventuelt med metoksy mono-, di- eller tri-substituert fenylrest, karakterisert ved at man anvender tilsvarende substituerte utgangsmaterialer.
3. Fremgangsmåte ifølge krav 1 for fremstilling av 1-benzyl-4-hydroksymetyl-pyrrolidin-2-on, karakterisert ved at man anvender tilsvarende substituerte utgangsmaterialer.
4. Fremgangsmåte ifølge krav 1 for fremstilling av 1-(4-metoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on, karakterisert ved at man anvender tilsvarende substituerte utgangsmaterialer.
5. Fremgangsmåte ifølge krav 1 for fremstilling av 1-(3,4-dimetoksybenzyl)-4-hydroksymetyl-pyrrolidin-2-on, karakterisert ved at man anvender tilsvarende substituerte utgangsmaterialer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19833326724 DE3326724A1 (de) | 1983-07-25 | 1983-07-25 | In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte |
Publications (3)
Publication Number | Publication Date |
---|---|
NO843004L NO843004L (no) | 1985-01-28 |
NO163814B true NO163814B (no) | 1990-04-17 |
NO163814C NO163814C (no) | 1990-07-25 |
Family
ID=6204831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO843004A NO163814C (no) | 1983-07-25 | 1984-07-24 | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-substituerte 4-hydroksymetyl-pyrrolidinon-derivater. |
Country Status (24)
Country | Link |
---|---|
US (1) | US4581364A (no) |
EP (1) | EP0132811B1 (no) |
JP (1) | JPS6051172A (no) |
KR (1) | KR910003613B1 (no) |
AT (1) | ATE37537T1 (no) |
AU (1) | AU568863B2 (no) |
CA (1) | CA1253159A (no) |
CS (1) | CS244447B2 (no) |
DD (1) | DD233125A5 (no) |
DE (2) | DE3326724A1 (no) |
DK (1) | DK362584A (no) |
ES (1) | ES8602649A1 (no) |
FI (1) | FI78463C (no) |
GR (1) | GR82221B (no) |
HU (1) | HU192039B (no) |
IL (1) | IL72477A (no) |
NO (1) | NO163814C (no) |
NZ (1) | NZ208990A (no) |
PH (1) | PH21119A (no) |
PL (1) | PL142583B1 (no) |
PT (1) | PT78968B (no) |
SU (1) | SU1498385A3 (no) |
YU (1) | YU42901B (no) |
ZA (1) | ZA845697B (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3336024A1 (de) * | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
JPH066571B2 (ja) * | 1985-05-09 | 1994-01-26 | エーザイ株式会社 | 2−ピロリドン誘導体 |
US4700244A (en) * | 1986-02-14 | 1987-10-13 | Hewlett-Packard Company | Process and system for compensating for information shifts on disc storage media |
DE3706399A1 (de) * | 1987-02-27 | 1988-09-08 | Boehringer Ingelheim Kg | Mittel mit antidepressiver wirkung |
US4981974A (en) * | 1989-05-08 | 1991-01-01 | Gaf Chemicals Corporation | Polymerizable pyrrolidonyl oxazoline monomers |
IT1231921B (it) * | 1989-06-12 | 1992-01-15 | Sigma Tau Ind Farmaceuti | 1-acil-2-pirrolidoni quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
DE69025840T2 (de) * | 1989-09-29 | 1996-10-17 | Seagate Technology | Verfahren und Gerät zum Erfassen von Positionierungsfehlern eines Schreib/Lesekopfes |
CA2842660C (en) * | 2011-07-21 | 2019-05-28 | The Lubrizol Corporation | Carboxylic pyrrolidinones and methods of use thereof |
CA2842669A1 (en) * | 2011-07-21 | 2013-01-24 | The Lubrizol Corporation | Overbased friction modifiers and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1039113A (en) * | 1964-08-06 | 1966-08-17 | Ucb Sa | New n-substituted lactams |
DE2454325A1 (de) * | 1974-11-15 | 1976-05-20 | Bayer Ag | Zusatzbeschleuniger enthaltende ungesaettigte polyesterharze |
US4119637A (en) * | 1975-09-23 | 1978-10-10 | A. H. Robins Company, Inc. | 4-Hydroxymethyl-2-pyrrolidinones |
JPS5246067A (en) * | 1975-10-07 | 1977-04-12 | Teijin Ltd | Reduction of optically active 5-oxo-2-pyrrolidinacetic acid esters |
US4144245A (en) * | 1977-05-11 | 1979-03-13 | A. H. Robins Company, Inc. | 4-Hydroxymethyl-2-pyrrolidinones |
DE2757680A1 (de) * | 1977-12-23 | 1979-06-28 | Troponwerke Gmbh & Co Kg | Neue 2-oxo-1-pyrrolidinessigsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
CU21107A3 (es) * | 1978-02-10 | 1988-02-01 | Hoffmann La Roche | Pyrrolidines derivatives |
DE2923975A1 (de) * | 1979-06-13 | 1980-12-18 | Nattermann A & Cie | Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel |
CH657527A5 (de) * | 1980-02-13 | 1986-09-15 | Ciba Geigy Ag | Verwendung von zentralnervoes-wirksamen verbindungen in einem mittel, welches zur verhinderung oder linderung von nebenwirkungen bestimmt ist. |
DE3031118A1 (de) * | 1980-08-18 | 1982-04-01 | Meditest Institut für medizinisch-pharmazeutische Untersuchungen GmbH & Co KG, 7958 Laupheim | N,n'-bis(5-oxo-1-methyl-pyrrolidin-2-yl-essigsaeure)-hydrazid, verfahren zu dessen herstellung und seine verwendung als arzneimittel |
DE3336024A1 (de) * | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
-
1983
- 1983-07-25 DE DE19833326724 patent/DE3326724A1/de not_active Withdrawn
-
1984
- 1984-07-09 US US06/628,739 patent/US4581364A/en not_active Expired - Lifetime
- 1984-07-20 IL IL72477A patent/IL72477A/xx unknown
- 1984-07-20 SU SU843767329A patent/SU1498385A3/ru active
- 1984-07-21 EP EP84108642A patent/EP0132811B1/de not_active Expired
- 1984-07-21 AT AT84108642T patent/ATE37537T1/de not_active IP Right Cessation
- 1984-07-21 DE DE8484108642T patent/DE3474300D1/de not_active Expired
- 1984-07-23 YU YU1308/84A patent/YU42901B/xx unknown
- 1984-07-23 GR GR75405A patent/GR82221B/el unknown
- 1984-07-23 PL PL1984248898A patent/PL142583B1/pl unknown
- 1984-07-23 DD DD84265563A patent/DD233125A5/de unknown
- 1984-07-24 NO NO843004A patent/NO163814C/no unknown
- 1984-07-24 ES ES534587A patent/ES8602649A1/es not_active Expired
- 1984-07-24 NZ NZ208990A patent/NZ208990A/en unknown
- 1984-07-24 PT PT78968A patent/PT78968B/pt unknown
- 1984-07-24 DK DK362584A patent/DK362584A/da not_active Application Discontinuation
- 1984-07-24 CA CA000459535A patent/CA1253159A/en not_active Expired
- 1984-07-24 KR KR1019840004385A patent/KR910003613B1/ko active IP Right Grant
- 1984-07-24 CS CS845710A patent/CS244447B2/cs unknown
- 1984-07-24 ZA ZA845697A patent/ZA845697B/xx unknown
- 1984-07-24 AU AU31101/84A patent/AU568863B2/en not_active Ceased
- 1984-07-24 HU HU842855A patent/HU192039B/hu not_active IP Right Cessation
- 1984-07-25 PH PH31028A patent/PH21119A/en unknown
- 1984-07-25 FI FI842955A patent/FI78463C/fi not_active IP Right Cessation
- 1984-07-25 JP JP59155102A patent/JPS6051172A/ja active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910007882B1 (ko) | 1-벤질-아미노알킬-피롤리디논의 제조방법 | |
FR2555584A1 (fr) | Derives de l'acide fluoro-6-dihydro-1,4-oxo-4-piperazinyl substitue-7-quinoline-carboxylique-3 et procede pour leur preparation et compositions pharmaceutiques a action anti-bacteriennes a base desdits derives | |
EP0009425A1 (en) | Novel naphtyridine derivatives and pharmaceutical compositions containing them | |
NO162977B (no) | Filt for fremstilling av en vaatpressefilt for en papirmaskin, samt fremgangsmaate ved fremstilling derav. | |
NO137440B (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive pleuromutiliner | |
NO163814B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-substituerte 4-hydroksymetyl-pyrrolidinon-derivater. | |
DE2504250A1 (de) | Tetrahydroisochinolin-derivate und verfahren zu ihrer herstellung | |
HU193393B (en) | Process for preparing new, substituted pyrrolidinones | |
BE823841A (fr) | Derives de 5-(1-hydroxy-2-amino substitue) alkyl-8-carbostyryle substitue et de 5-(1-hydroxy-2-amino substitue) alkyl-8-(3,4-dihydro) carbostyryle substitue et leur procede de preparation | |
NO163597B (no) | Styreinnretning for et ett-eller tosporet kjoeretoey. | |
US3818090A (en) | Novel quinolines in the treatment of pain and inflammation | |
AU2004268896A1 (en) | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
US4479952A (en) | Monosubstituted piperazines | |
US4256753A (en) | 4-(2-Pyridylamino)phenylacetic acid derivatives | |
US3687936A (en) | 11-AMINOALIPHATIC-5:10-METHANODIBENZO {8 a:d{9 {0 {8 1:4{9 {0 CYCLOHEPTADIENES AND THE SALTS THEREOF | |
NO150280B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 9-aminopyrido(1,2-a)pyrimidinderivater | |
US3211745A (en) | Demvatives of j-cyclopropylamesfo- methyl-indole | |
KR800000492B1 (ko) | 4-하이드록시-2H-나프토[2, 1-e]-1, 2-티아진-3-카복사마이드-1, 1-디옥사이드류의 제조방법 | |
CA1133494A (en) | Substituted 4-aryl-2,5-dihydro-furane- 2-ones and 4-aryl-1,5-dihydro-2h-pyrrole-2-ones and method of their production | |
BE875470A (fr) | Composes piperazinyl-benzoheterocycliques, leur preparation et leurs utilisations therapeutiques | |
US3591595A (en) | Certain 2 - hydroxyloweralkyl-tetrahydro-2-h-indeno(1,2-c) pyridines and 2-hydroxy loweralkyl-hexahydro-2-h-indeno(1,2-c) pyridin 5-ols | |
EP0278265A1 (en) | 1- [(4-Morpholinyl) alkyl] -1H-indoles useful as analgesics and preparation thereof | |
EP0384844A2 (fr) | Nouveaux dérivés de la 1-arylsulfonyl pyrrollidin-2-thione ou de la 1-aryl-sulfonyl pipéridin-2-thione, leur procédé de préparation, leur application comme médicaments et les compositions les renfermant | |
HU197316B (en) | Process for production of n-imidasolile-metil-diphenilazo-methin derivatives and medical compounds containing them | |
NO144671B (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive n-(p-fluorbenzoylpropyl)-4-piperidylamider |